We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Biosearch Launches Catalogued Stellaris™ RNA FISH Assays

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Biosearch Launches Catalogued Stellaris™ RNA FISH Assays"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Biosearch Technologies, Inc. (Biosearch) has announced that the company has launched catalogued assays for Stellaris™ RNA FISH.

These assays fall into three groups - well characterized RNA targets (“foundation genes”) suitable for use as positive controls, oncogenes, and key mRNAs in the hypusine pathway.

Scientists can use these products to pursue research using RNA FISH and combine them into multiplexed assays with probes targeting other RNA transcripts or even protein targets.

For example, immunofluorescence (IF) techniques may be readily combined with Stellaris RNA FISH.

Biosearch announced on August 5th 2010 that the company had licensed exclusive rights to a fluorescent in situ hybridization (FISH) technology for detection of single molecules of RNA.

Biosearch owns the exclusive rights to manufacture, catalogue and sell RNA FISH probes, assays and kits into the Research, Applied Markets and in vitro diagnostics (IVD) fields under the UMDNJ technologies and patent applications, and currently makes these products available as Stellaris RNA FISH probes.

The launch of catalogued Stellaris products will significantly improve ease of use for the Stellaris technology by providing convenient positive controls, and reducing uncertainty associated with designing an untested probe set against a new RNA target.

Cancer research may benefit from the assays designed against prevalent oncogenes, and upcoming additions of cancer related RNA targets.

The team at Biosearch also plans to provide the same advantages in the future to developmental biology, neuroscience, and other specialties.

This product is sold under license from the University of Medicine and Dentistry of New Jersey and may be used under its patent rights for Research Use Only.